Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: "They are heroic, I think there is no other way to describe what they are doing at this moment," said Howard Catton, a British nurse who is the ICN's chief executive officer. Infection rates of 9% and 12-14% have been reported among health workers in Italy and Spain, respectively, and deaths among nurses there and in Iran and Indonesia, he said. "We have no doubt that the rate of infections is related in part to the lack of PPE - personal protective equipment," he told Reuters at the ICN offices along Lake Geneva. "There is a global shortage and nurses obviously are at a higher risk given the people that they are caring for." The federation represents 130 national associations and more than 20 million registered nurses. The World Health Organization has called repeatedly for countries and manufacturers to step up production of masks, gloves, gowns and other equipment for vulnerable health workers amidst critical shortages. Nearly 700,000 people have been infected worldwide in the outbreak that began last December in China and has claimed more than 33,000 lives, according to the WHO. Catton said there had been problems with supply chains in hard-hit Italy and Spain, describing their health systems as "very close to being overwhelmed". Nurses worldwide take samples from COVID-19 patients, give them medicines and oxygen, and help incubate those in serious condition. "They are working under intense pressure, often long hours, some working back-to-back shifts for days on end, even sleeping over in the hospital, the facility, in which they work." Some nurses have been forced to re-use their gear or make their own masks and gowns, he added. "Wearing personal protective equipment when it is available is not easy either...Simple things like going to the loo and eating are of course much more difficult," he said. Nurses across Africa and South Asia could be at greater risk as the virus moves to poorer settings. "We are very concerned that those countries that have weaker, more fragile health care systems could very quickly become overwhelmed by this virus if it takes hold in their countries," Catton said. Nurses in Zimbabwe, fearing for their own safety, have been on strike due to a lack of information and protective gear, he said.
[A]: Heroic nurses need full protection against coronavirus, association says.

[Q]: Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure. "In the past, 10 programs were chosen, a budget for eight was allocated. Usually what happened was that time was the trade off that was made," he said in an interview. "Now what we do is we pick five or six programs, and concentrate investment there." GSK, like rivals, was in the habit of testing new drugs first on patients who had run out of other treatment options. If successful, it would try patients at an earlier stage of their disease, replacing older, established treatments. In today's market, where rivals in the United States and China catch up fast if a new class of drug shows promise, GSK has to run costly drug tests on humans in several settings at the same time, even if it means dropping other drug candidates. "Rather than do things sequentially, you do them in parallel, or as close to parallel as possible," Miels said. GSK, which is battling to return to profit growth, has taken this approach for instance with an experimental drug that for now goes by the code name of GSK'916 against multiple myeloma, a common and incurable type of blood cancer. Likewise, GSK doubled down on its quest to bring a drug known as GSK'165 to market as a rheumatoid arthritis treatment, even after initial results in a mid-stage drug trial did not show a clear enough reading. "This drug has very interesting effects on pain. That could potentially reduce the use of opioids and pain meds," Miels said. More trials will be run to make the pain argument more clearly, he added. GSK expects a decline of 5%-9% in adjusted earnings per share this year, excluding exchange rate moves, as it suffers from generic competition to its inhalable lung drug Advair and pressure from rival Gilead in HIV treatments. Miels said a tougher stance on drug prices by U.S. lawmakers and medical insurers was one of the reasons for the need for speed in bringing drugs to market - to try to remain ahead of competitors for as long as possible. At the same time, rapid growth in the Chinese market was spurring a more sophisticated healthcare system there, with local biotech groups quick to catch up with Western pioneers in drug development, producing similar drugs for their home market.
[A]: GSK pharma head flags need for speed in high-pressure drug market.

[Q]: The new list price for Praluent will be $5,850 a year, matching the price Amgen set when it lowered the list of its competing drug, Repatha, in October. Sanofi and Regeneron said they expect the lower-priced Praluent to be available for pharmacies to order in early March. They said the new price should improve patient access and result in lower out-of-pocket costs for U.S. consumers. Praluent and Repatha belong a class of injectable biotech drugs called PCSK9 inhibitors that dramatically lower bad LDL cholesterol and reduce the risk of heart attacks and death. Sales of both have been severely constrained by onerous roadblocks to patient access put up by insurers looking to limit spending on the expensive drugs. They were approved in 2015 with initial list prices of more than $14,000 a year. In March of last year, Regeneron and Sanofi said that they would be willing to charge less for their drug if insurers agreed to reduce barriers for high-risk heart patients. A few months later they struck a deal with Express Scripts, now part of Cigna Corp, to make the drug available to that company's customers at a price in the range of $4,500 to $6,600 a year. The United States, which leaves drug pricing to market competition, has higher prices than in other developed countries, where governments directly or indirectly control costs. That makes it by far the world's most lucrative market for manufacturers. Congress has been targeting the pharmaceutical industry over the rising cost of prescription drugs for U.S. consumers, particularly since Democrats took over the House of Representatives in January. Executives from at least six drugmakers plan to testify at a Senate hearing on rising prescription drug prices later this month. Drug pricing is also a top priority of the administration of President Donald Trump, who had made it a central issue of the 2016 presidential campaign.
[A]:
Sanofi and Regeneron cut list price of cholesterol drug by 60 percent.